Evidence map›Paper›PMID 31053995›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2019

Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients.

Zeeshan Hamid, Abdul Basit, Silvia Pontis, Fabrizio Piras, Francesca Assogna, Paola Bossù, Francesco Ernesto Pontieri, Alessandro Stefani, Gianfranco Spalletta, Pietro Franceschi and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Zeeshan HamidD3Validation, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy.
Abdul BasitD3Validation, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy.
Silvia PontisD3Validation, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy.
Fabrizio PirasLaboratorio di Neuropsichiatria, IRCCS Fondazione Santa Lucia, Via Ardeatina, 306, 00179, Rome, Italy.
Francesca AssognaLaboratorio di Neuropsichiatria, IRCCS Fondazione Santa Lucia, Via Ardeatina, 306, 00179, Rome, Italy.
Paola BossùLaboratorio di Neuropsichiatria, IRCCS Fondazione Santa Lucia, Via Ardeatina, 306, 00179, Rome, Italy.
Francesco Ernesto PontieriLaboratorio di Neuropsichiatria, IRCCS Fondazione Santa Lucia, Via Ardeatina, 306, 00179, Rome, Italy.
Alessandro StefaniDepartment of Medicine of Systems, Tor Vergata University, Viale Oxford 81, 00133, Rome, Italy.
Gianfranco SpallettaLaboratorio di Neuropsichiatria, IRCCS Fondazione Santa Lucia, Via Ardeatina, 306, 00179, Rome, Italy.
Pietro FranceschiComputational Biology Unit, Research and Innovation Centre, Fondazione Edmund Mach, Via E. Mach 1, San Michele all'Adige, TN, Italy.
Angelo ReggianiD3Validation, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy.
Andrea ArmirottiAnalytical Chemistry Lab, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy. andrea.armirotti@iit.it.ORCID 0000-0002-3766-8755
Fondazione Santa Lucia · ITItalian Institute of Technology · ITFondazione Edmund Mach · ITScuola Superiore Sant'Anna · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent markers of Parkinson's disease (PD) fail to detect the early progression of disease state. Conversely, current omics techniques allow the investigation of hundreds of molecules potentially altered by disease conditions. Based on evidence previously collected by our group in a mouse model of PD, we speculated that a particular set of circulating lipids might be significantly altered by the pathology.

objectivesThe aim of current study was to evaluate the potential of a particular set of N-acyl-phosphatidylethanolamines (NAPEs) as potential non-invasive plasma markers of ongoing neurodegeneration from Parkinson's disease in human subjects.

methodsA panel of seven NAPEs were quantified by LC-MS/MS in the plasma of 587 individuals (healthy controls, n = 319; Parkinson's disease, n = 268); Random Forest classification and statistical modeling was applied to compare Parkinson's disease versus controls. All p-values obtained in different tests were corrected for multiplicity by controlling the false discovery rate (FDR).

resultsThe results indicate that this panel of NAPEs is able to distinguish female PD patients from the corresponding healthy controls. Further to this, the observed downregulation of these NAPEs is in line with the results in plasma of a mouse model of Parkinson's (6-OHDA).

conclusionsIn the current study we have shown the downregulation of NAPEs in plasma of PD patients and we thus speculate that these lipids might serve as candidate biomarkers for PD. We also suggest a molecular mechanism, explaining our findings, which involves gut microbiota.

Indexed as

MetabolomicsAdultAgedAged, 80 and overAnimalsFemaleHumansMaleMiceMiddle AgedParkinson DiseasePhosphatidylethanolaminesSex FactorsYoung AdultN-acylphosphatidylethanolaminePhosphatidylethanolaminesLipid biomarkersNAPEParkinson’s disease

Identifiers

PMID31053995
PMCPMC6499742
OpenAlexW2942887117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.